Show Menu

A fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events

News: Latest Posts

Acquisition of Sanofi Pasteur’s Equine Antivenom Immunoglobulin Products

MicroPharm Limited is pleased to announce the acquisition of Sanofi Pasteur’s antivenom equine immunoglobulin product range comprising Viperfav®, Bothrofav® Scorpifav®, Fav-Afrique® and Favirept®.

Read the full story

Posted on: Tuesday, 2nd January 2018

MicroPharm Secures Biomedical Catalyst 2016 Grant

MicroPharm Limited announced that it has secured a grant of £195,567 to further support the development of OraCAb, a therapeutic for oral administration of polyclonal antibodies to treat Clostridium difficile infections.

Read the full story

Posted on: Wednesday, 1st February 2017

MicroPharm Secures SMART Grant

MicroPharm Limited announced that it has secured a grant of £195,373 to further support the development of OraCAb, a therapeutic for oral administration of polyclonal antibodies to treat Clostridium difficile infections. This is funding from the European Regional Development Fund (ERDF) under the Welsh government operational programme SMART Cymru West Wales and the Valleys 2014-2020.

Read the full story

Posted on: Thursday, 1st December 2016

Contract Awarded for Manufacture of a Ricin Antitoxin

MicroPharm Limited is pleased to announce the award of a contract offered by the Defence Science and Technology Laboratory (Dstl) on behalf of the Ministry of Defence (MOD) to manufacture a ricin antitoxin. 

Read the full story

Posted on: Tuesday, 23rd August 2016

MicroPharm-PHE Ebola Partnership in the Spotlight

MicroPharm is pleased to announce that its promising ovine polyclonal antibody against Ebola, developed in collaboration with Public Health England (PHE) and the University of Oxford, has been in the spotlight as an example of good practice in knowledge exchange and commercialisation.

Read the full story

Posted on: Friday, 16th October 2015